3/6/2024 0 Comments Parasite in city stage 3![]() cruzi, and at risk of developing clinical Chagas disease, which affects over 7 million people worldwide,β said Eric Easom, Co-Founder, President, and Chief Executive Officer of AN2 Therapeutics. βAN2-502998 has the potential to be a game-changer for the treatment of individuals infected with T. ![]() To date, preclinical activities have been supported using non dilutive grant funding from Wellcome and are conducted in partnership with Professor Tarleton. The lead compound under this series, AN2-502998 (formerly known as AN15368), was discovered in close collaboration with Professor Rick Tarleton, Ph.D., University of Georgia, an expert in Chagas disease and Trypanosoma cruzi biology. (a wholly owned subsidiary of Pfizer) and the University of Georgia, with grant funding from Wellcome. These boron-based molecules were originally discovered by researchers at Anacor Pharmaceuticals, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced that it has received an exclusive license from the University of Georgia Research Foundation to advance the development of a boron-containing small molecule for Chagas disease.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |